Treatment is in fact a real challenge. Cryptococcus isolates "in the wild" have a relatively high frequency of azole resistance alleles already (azoles are what you give someone for a typical "yeast" infection), and azole resistances arises relatively quickly in patients in both patients and animal models of disease. Coupled with this is the fact that fungi are eukaryotes, and hence share most of their core cell and molecular biology with your own cells. Hence treatments that specifically target the fungal cell with little toxicity to your own cells are hard to come by.

Note that last year the WHO released a list of "fungal priority pathogens" based on criteria related to "unmet research and development needs and perceived public health importance." Cryptococcus is at the top of this list.

https://www.who.int/publications/i/item/9789240060241

General resources on fungal meningitis:

https://www.cdc.gov/meningitis/fungal.html

CDC resources specific to Cryptococcus:

https://www.cdc.gov/fungal/diseases/cryptococcosis-neoforman...